BeOne presents BRUKINSA Phase 3 Data in CLL Patients Aged 80+ at EHA 2026

Denna nyhet är endast avsedd för press och mediaThis news is intended for press and media only Stockholm, Sweden – June 11, 2026 – BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up. Further, BRUKINSA demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.[1] These data will be presented at the 2026